Dynavax Technolo Stock Price, News & Analysis

Dynavax Technologies (DVAX) reported strong preliminary financial results for the year ending December 31, 2022. HEPLISAV-B vaccine's net product revenue reached approximately $126 million, marking a 104% growth year-over-year. The CpG 1018 adjuvant generated about $588 million in revenue. The company maintained a robust cash position with approximately $624 million in cash and investments. Additionally, topline results from the Phase 1 shingles trial indicated favorable tolerability and promising vaccine response rates compared to the comparator vaccine, Shingrix®.

Dynavax Technologies (Nasdaq: DVAX) announced its participation in two investor conferences, highlighting its role in developing innovative vaccines. The presentations will include a fireside chat at the Guggenheim Healthcare Talks on November 14, 2022, at 10:10 a.m. EST and another at the 5th Annual Evercore ISI HealthCONx Conference on November 29, 2022, at 10:05 a.m. EST. Investors can access live webcasts through the Company's website's 'Events & Presentations' section. Dynavax specializes in products like HEPLISAV-B and the CpG 1018 adjuvant.

Dynavax Technologies Corporation (Nasdaq: DVAX) reported Q3 2022 total revenue of $167.7 million, reflecting a 55% increase from $108.3 million in Q3 2021. HEPLISAV-B® vaccine revenue reached $37.5 million, up 65% year-over-year, while CpG 1018® adjuvant revenue was $126.3 million, a 50% rise. The company reaffirmed its full-year guidance for CpG 1018 revenue between $550 million and $600 million. Notably, Dynavax anticipates a second consecutive year of profitability, with a reported GAAP net income of $63.8 million for the quarter.

Dynavax Technologies Corporation (Nasdaq: DVAX) is set to report its third quarter financial results on November 3, 2022, post-market close. The company will also host a conference call at 4:30 p.m. ET. Both the call and a following audio webcast will be accessible on Dynavax's investor relations page. Dynavax specializes in developing vaccines, notably its approved products, HEPLISAV-B and the CpG 1018 adjuvant, which is instrumental in various COVID-19 vaccine formulations. More details are available on the company’s website.

Dynavax Technologies Corporation (Nasdaq: DVAX) has announced that CEO Ryan Spencer will present at the H.C. Wainwright 3rd Annual Hepatitis B Virus Virtual Conference on October 18, 2022, at 10:00 a.m. P.T.. This presentation will be available via webcast on the company's website under the 'Events & Presentations' section. Dynavax focuses on innovative vaccines, with two commercial products: HEPLISAV-B and CpG 1018 adjuvant, aimed at preventing hepatitis B and enhancing various vaccines, respectively.

Dynavax Technologies Corporation (Nasdaq: DVAX) has announced the dosing of the first participant in a Phase 2 clinical trial for the adjuvanted plague vaccine, developed in collaboration with the U.S. Department of Defense. This trial evaluates the immunogenicity and safety of the recombinant plague vaccine combined with Dynavax's CpG 1018 adjuvant. The funding for this initiative is approximately $22 million over two and a half years. The trial aims to assess a two-dose regimen over one month, potentially shortening the standard three-dose schedule. The CpG 1018 adjuvant has previously shown safety in various vaccines.

Dynavax Technologies Corporation (Nasdaq: DVAX) will have CEO Ryan Spencer participate in a virtual fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The on-demand presentation will be available from September 12, 2022, at 7:00 a.m. E.T., accessible via the Investors section on Dynavax's website. The company focuses on innovative vaccines, with products like HEPLISAV-B® and CpG 1018® adjuvant, aimed at combating infectious diseases. For more information, visit www.dynavax.com.

Dynavax Technologies (DVAX) reported Q2 2022 total revenue of $256.5 million, a remarkable 386% increase from $52.8 million in Q2 2021. Notable revenue includes $32.7 million from the HEPLISAV-B vaccine, up 139%, and $222.6 million from CpG 1018 adjuvant sales, skyrocketing by 471%. The company is on track for a second consecutive year of profitability. GAAP net income reached $128.8 million or $1.02 per share. With cash reserves of $518.2 million, Dynavax anticipates full-year revenues between $550 million and $600 million for CpG 1018 adjuvant.

Dynavax Technologies Corporation (Nasdaq: DVAX) is set to report its second quarter financial results on August 4, 2022, post-market close. The company will also host a conference call and live audio webcast at 4:30 p.m. ET. Interested parties can access the webcast via the company's website. Dynavax is known for its innovative vaccines, including HEPLISAV-B for hepatitis B and the CpG 1018 adjuvant, which is utilized in various COVID-19 vaccines. The forthcoming financial results are highly anticipated by investors.